医学
脂肪变性
内科学
价值(数学)
胃肠病学
代谢综合征
脂肪肝
疾病
心脏病学
糖尿病
作者
Ying Xiao,Sizhuang Huang,Hongzhao You,Dong Liu,Jiansong Yuan,俞梦越,Weixian Yang
出处
期刊:JACC
[Elsevier BV]
日期:2026-10-01
卷期号:: 103378-103378
标识
DOI:10.1016/j.jacadv.2026.103378
摘要
Background Hepatic steatosis carries substantial cardiovascular risk, whereas cardiovascular-kidney-metabolic (CKM) syndrome contributes to liver disease progression, highlighting the need for integrated cardiohepatic risk assessment. Objectives The objective of the study was to evaluate whether hepatic steatosis provides incremental prognostic value beyond CKM staging for cardiovascular and liver outcomes. Methods We included 313,970 UK Biobank participants with CKM stages 0 to 3. Hepatic steatosis was primarily assessed using the Fatty Liver Index, with the Hepatic Steatosis Index as an alternative measure and the Fibrosis-4 Index for liver fibrosis. The primary outcome was major adverse cardiovascular events (MACEs). The secondary outcome was major adverse liver events (MALEs). Results During a median 15.7-year follow-up, 32,110 MACEs and 1,599 MALEs occurred. Hepatic steatosis and advanced CKM were independently associated with both outcomes, with coexistence conferring the highest risks (MACEs: HR: 2.33; 95% CI: 2.19-2.47; MALEs: HR: 5.09; 95% CI: 3.97-6.54, vs neither exposure). For MACEs, the association with hepatic steatosis was stronger in nonadvanced CKM (stages 0-2: HR: 1.51; 95% CI: 1.48-1.55) than in stage 3 (HR: 1.09; 95% CI: 0.97-1.23; P interaction < 0.001). For MALEs, hepatic steatosis mediated 41.1% of the association with CKM stage. The findings were consistent across alternative steatosis measures, whereas liver fibrosis showed no significant stage-dependent association with MACEs and a smaller mediation proportion for MALEs. Adding hepatic steatosis to CKM staging improved discrimination for both outcomes. Conclusions Hepatic steatosis provided complementary cardiovascular and liver prognostic value beyond CKM staging, supporting its integration for more comprehensive cardiohepatic risk stratification.
科研通智能强力驱动
Strongly Powered by AbleSci AI